Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Ken Bridges"'
Publikováno v:
Annals of internal medicine. 174(7)
Autor:
Johan Vansteenkiste, Jean-Luc Canon, Ken Bridges, B. Pujol, Carsten Bokemeyer, Heinz Ludwig, Jason C. Legg, Pere Gascón, Jan B. Vermorken, Michael Hedenus
Publikováno v:
Medical Oncology. 29:2291-2299
Darbepoetin alfa (DA) is an erythropoiesis-stimulating agent (ESA) approved for treating chemotherapy-induced anemia (CIA). Safety concerns have prompted changes to the ESA-product information, which now recommends initiating ESAs at hemoglobin (Hb)
Autor:
John A. Glaspy, Ken Bridges, Alex Fleishman, Jeffrey Crawford, Anders Österborg, Johan Vansteenkiste, Heinz Ludwig, David H. Henry
Publikováno v:
Journal of Clinical Oncology. 27:2838-2847
Purpose Although numerous clinical trials have demonstrated the efficacy and tolerability of erythropoiesis-stimulating agents (ESAs) in patients with chemotherapy-induced anemia (CIA), results of some recent trials and one meta-analysis have suggest
Publikováno v:
Blood. 126:5608-5608
Background With the advancements in relapsed multiple myeloma (RMM) treatments and healthcare resource constraints, it is important to understand the impact of response to RMM treatments on healthcare resource utilization (HRU). We conducted a consen
Autor:
Johan Vansteenkiste, Jeffrey Crawford, John A. Glaspy, Ken Bridges, S. Rao, Dianne Tomita, Peter Bowers, Heinz Ludwig, David H. Henry, J A Berlin
Publikováno v:
British Journal of Cancer
British journal of cancer, vol 102, iss 2
British journal of cancer, vol 102, iss 2
BACKGROUND: Cancer patients often develop the potentially debilitating condition of anaemia. Numerous controlled studies indicate that erythropoiesis-stimulating agents (ESAs) can raise haemoglobin levels and reduce transfusion requirements in anaemi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2c1e5184386b9e7f95357e09ea54ba4
https://lirias.kuleuven.be/handle/123456789/624643
https://lirias.kuleuven.be/handle/123456789/624643
Autor:
Jason C. Legg, Michael Hedenus, B. Pujol, Johan Vansteenkiste, J. R. Canon, Ken Bridges, Carsten Bokemeyer, Heinz Ludwig, Pere Gascón, Jan B. Vermorken
Publikováno v:
Journal of Clinical Oncology. 28:9077-9077
9077 Background: DA is an erythropoiesis-stimulating agent (ESA) approved in the US and EU to treat CIA based on controlled studies showing a reduction in transfusion needs and an increase in Hb le...
Publikováno v:
Journal of Clinical Oncology. 27:6616-6616
6616 Background: Heparin is an effective treatment option for the prevention of venous thromboembolism (VTE) in cancer patients on chemotherapy. To date, information on the use of both low molecular weight heparin (LMWH) and non-LMWH in cancer patien
Autor:
Ken Bridges, Michael Hedenus, Lisa Hamilton, B. Pujol, Carsten Bokemeyer, Heinz Ludwig, Pere Gascón, Jan B. Vermorken, Johan Vansteenkiste
Publikováno v:
BMC Cancer, Vol 9, Iss 1, p 311 (2009)
BMC Cancer
BMC Cancer
Background Several studies have shown that darbepoetin alfa, an erythropoiesis-stimulating agent (ESA), can reduce transfusions and increase hemoglobin (Hb) levels in patients with chemotherapy-induced anemia (CIA). Recent safety concerns, however, h
Publikováno v:
Public Works; Spring2010, Vol. 141 Issue 6, p99-100, 2p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.